This trial tests the safety & effectiveness of a drug to treat advanced cancers including lung, esophageal, renal and head/neck cancer.
- Esophageal Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer
4 Primary · 12 Secondary · Reporting Duration: Up to 31 months
2 Treatment Groups
Part 2: Dose expansion
1 of 2
Part 1: Dose escalation
1 of 2
125 Total Participants · 2 Treatment Groups
Primary Treatment: Part 2: Dose expansion · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Part 2: Dose Expansion of this project been granted clearance by the U.S. Food and Drug Administration?
"Our team at Power has judged Part 2: Dose Expansion to have a score of 1 due to its Phase 1 status, which implies limited pre-existing evidence verifying the medication's safety and efficacy." - Anonymous Online Contributor
Are medical professionals currently looking for participants in this trial?
"Affirmative, the data hosted on clinicaltrials.gov indicates that this medical research is currently seeking new participants. This trial was initially published on January 31st 2023 and has been updated most recently by January 11th of the same year. 125 people are expected to join at one location for this project." - Anonymous Online Contributor
What are the fundamental aims of this experiment?
"Novartis Pharmaceuticals, the sponsor of this study, has outlined that over a 30-month period they will be assessing Frequency of dose interruptions and reductions as its primary outcome. Additionally, secondary objectives such as Elimination half-life (T1/2) of QEQ278, Total body clearance (CL)of QEQ278, and Volume of distribution (Vz)of QEQ278 will also be evaluated." - Anonymous Online Contributor
What is the approximate number of participants enrolled in this clinical experiment?
"Yes, according to the latest information on clinicaltrials.gov, this experiment is presently recruiting patients for participation. The research commenced on January 31st 2023 and was recently updated on January 11th 2023; with a need of 125 individuals from one site." - Anonymous Online Contributor